Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (NYSE: BDX) is a global leader in medical technology driving advancements in healthcare through innovative devices, diagnostic solutions, and clinical systems. This page provides real-time updates on BD's latest developments, offering investors and professionals a centralized hub for tracking corporate announcements and industry impact.
Access authoritative information including earnings reports, regulatory milestones, product innovations, and strategic partnerships. Our curated news collection helps stakeholders monitor BD's contributions to medication management, diagnostic testing, and surgical care across 190+ countries.
Key updates cover BD Medical safety-engineered products, BD Life Sciences diagnostic platforms, and BD Interventional surgical technologies. Stay informed about developments in smart medication systems, infectious disease testing, and minimally invasive procedures shaping modern healthcare.
Bookmark this page for ongoing insights into BD's operational updates, leadership changes, and R&D breakthroughs. Verify critical information directly through primary sources while maintaining awareness of market trends in the $600B+ medical technology sector.
BD (Becton, Dickinson and Company) will announce its third quarter fiscal 2021 financial results on August 5, 2021, at approximately 6:00 a.m. ET. A conference call will follow at 8:00 a.m. ET for discussions on the results, operations, and strategy. The event will be available for replay until August 12, 2021. Additionally, BD plans to host an Investor Day on November 12, 2021, with more details to be shared later. For further information, visit bd.com/investors.
BD (Becton, Dickinson and Company) announced it received 510(k) clearance from the FDA for its PeritX™ Peritoneal Catheter System to drain symptomatic, recurrent non-malignant ascites. This system, which expands on the existing PleurX™ system, allows patients to manage their condition at home, reducing hospital visits. The PeritX™ is now the first FDA-approved tunneled catheter for both malignant and non-malignant ascites, improving patient care and comfort.
BD (Becton, Dickinson and Company) has partnered with USA Swimming to provide COVID-19 testing using the BD Veritor™ Plus System at various swimming events, including the U.S. Olympic Team Trials in June 2021. This initiative includes over 2,000 rapid antigen tests, supplementing existing PCR testing protocols to enhance athlete safety. BD's rapid testing technology delivers results in 15 minutes, promoting health and safety for competitors. This collaboration underscores BD's commitment to supporting athletes and ensuring safe participation in sports amidst the pandemic.
BD (Becton, Dickinson and Company) has secured pandemic orders for 2 billion injection devices to aid global COVID-19 vaccination efforts. This milestone includes commitments from over 40 countries and various NGOs. To date, BD has delivered over 900 million devices, with the remaining orders scheduled for delivery by the end of 2022. Additionally, BD plans to expand its manufacturing capacity with a $70 million project in Nebraska and invest $1.2 billion in upgrading facilities. The company was recognized at the 2021 World Vaccine Congress for its role in vaccination support.
BD (Becton, Dickinson and Company) has been named the first medical technology company to serve as a Common Vulnerability and Exposures (CVE) Numbering Authority. This designation allows BD to assign CVE ID numbers to new vulnerabilities in its software-enabled products, thus enhancing global cybersecurity efforts. The initiative aims to improve vulnerability management and assist customers in addressing cybersecurity risks. BD's established Coordinated Vulnerability Disclosure program and Cybersecurity Trust Center reflect its commitment to transparency and cybersecurity in medical devices.
BD (Becton, Dickinson and Company) announces its participation in two key virtual investor conferences in June 2021. The Piper Sandler June Med Tech Series Conference will take place on June 4 at 1:30 p.m. ET, followed by the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8 at 8:50 a.m. ET. Live webcasts of the presentations and related materials can be accessed via BD's investor website, with replays available for a minimum of seven days following each event.
BD (Becton, Dickinson and Company) has launched a new Urine Culture Application in the U.S. for the BD Kiestra™ lab automation system. This innovative application employs artificial intelligence and digital imaging to enhance urine culture analysis by efficiently categorizing samples based on growth significance. By automating the sorting process, it allows laboratories to prioritize critical specimens, thus increasing operational efficiency. The application is expected to support microbiology labs in managing their workloads, especially amid a skilled technician shortage exacerbated by the COVID-19 pandemic.
BD (Becton, Dickinson and Company) has launched the BD Surgiphor™ Sterile Wound Irrigation System, marking a significant advancement as the first ready-to-use aqueous povidone-iodine (PVP-I) irrigation solution. This product is designed to mechanically clean surgical wounds while providing a 99.99% reduction in bacteria. The system aims to simplify wound irrigation procedures for hospitals, adhering to safety standards set by U.S. health agencies. Acquired from Orthophor in November 2020, this product enhances BD's surgical portfolio, potentially increasing their market presence in the surgical domain.
BD (Becton, Dickinson and Company) will invest €165 million ($200 million USD) to establish a high-tech manufacturing facility in Zaragoza, Spain, projected to create 600 jobs by 2030. The construction is set to start in late 2021, contributing to BD's 2025 growth strategy of expanding pre-filled syringe manufacturing capacity. The new plant will be fully digital, aligning with sustainability standards, and aims to support COVID-19 vaccination efforts and other biologic drug deliveries in the European market.